Willard H. Dere
Independent Board ChairDr. Willard H. Dere, also known as Will, M.D. Ph.D. FACP, serves as Chief Medical Officer & Chief Advisor to CEO of Angitia Biopharmaceuticals Guangzhou Limited. He serves as an Independent Director at Metagenomi Therapeutics, Inc. (formerly known as Metagenomi, Inc.) since August 2021 and has been its Independent Board Chair since November 2025 and served as its Lead Independent Director since November 2024 until November 2025. He serves as a Member of Scientific Advisory Board at Heranova Lifesciences Inc. He served as Member of Scientific Advisors at Surrozen, Inc. He serves as Member of Scientific Advisory Board since June 2024 at MBX BioSciences, Inc. Dr. Dere has been Independent Director of Seres Therapeutics, Inc. since July 7, 2017. Since November 2014, Dr. Dere has been Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health and Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center and was Associate Vice President for Research since July 2019. Dr. Dere has served as Co-Director of the Center for Clinical and Translational Science and Co-Director of the Center for Genomic Medicine at University of Utah School of Medicine since November 2014. He is Co-Director of the Utah Center for Clinical and Translational Science. He served as the Corporate Chief Medical Officer and Acting Senior Vice President at Amgen Inc. since May 2014. He served as Senior Vice President of Global Development of Amgen Inc. since December 2004 until June 2007 and from April 2014 to October 2014 and as International Chief Medical Officer from January 2007 to April 2014. He served as Vice President of Amgen Inc. from July 8, 2003 to December 2004. He served as the Head of General Medicine for Amgen Inc. from July 12, 2004 to December 2004. He served as the Head of Inflammation Therapeutic Area for Amgen Inc. since July 8, 2003. He oversaw global development efforts for all new Inflammation product candidates and new indications for Amgen's marketed inflammation therapies, ENBREL(R) (etanercept) and Kineret(R) (anakinra). from 2003 until his retirement in October 2014, Dr. Dere held multiple roles at Amgen Inc. including Head of Global Development, International Research and Development and both Corporate and International Chief Medical Officer and led development of programs in various therapeutic areas at Eli Lilly & Company, where he served as Vice President of Endocrine, Bone and General Medicine Research and Development. He joined Amgen in 2003. He led teams that successfully registered new therapies for osteoporosis. He workedr at Eli Lilly in 1989 to 2014. Since 1989, Dr. Dere held an academic appointment at Indiana University School of Medicine, where he was Clinical Associate Professor and hospital appointments at Wishard Memorial Hospital and Richard Roudebush Veterans Administration Medical Center, where he taught physical diagnosis and was an attending Physician on the internal medicine service. He was an Assistant Professor at the University of Utah School of Medicine and held hospital appointments at the University of Utah Health Sciences Center and Veterans Administration Medical Center in Salt Lake City. Prior to re-joining academia, he was in the biopharmaceutical industry. Dr. Dere has served as Professor Emeritus of Internal Medicine at the University of Utah and an advisor to Angitia Biopharmaceuticals since June 2022. He has extensive academic experience and has knowledge in the biotechnology industry. He has been an Independent Director at BioMarin Pharmaceutical Inc. since July 18, 2016. He had been an Independent Director at Radius Health, Inc. since November 3, 2014 until August 10, 2022. He had been an Independent Director of Mersana Therapeutics, Inc. since March 19, 2018 until January 05, 2026. Dr. Dere has been Professor Emeritus, Department of Internal Medicine, at the University of Utah School of Medicine since July 2022. He is a Member of the Department of Medicine and Division of Endocrinology and Metabolism. He serves on the Scientific Advisory Board of the California Institute of Regenerative Medicine. He served as an Independent Director at Ocera Therapeutics, Inc. since October 26, 2016 until December 11, 2017. Dr. Dere has served as Chief Advisor to the Chief Executive Officer and Chief Medical Officer of Angita Bio since July 2022. He received numerous teaching awards from internal medicine house staff and medical students. He has published numerous articles, wrote and co-edited a primary care textbook, was awarded the 2008 transformational leadership award from his alma mater. He also held various roles in clinical pharmacology, regulatory affairs and both early-stage translational and late-stage clinical research at Eli Lilly and Company. He served on the Internal Medicine faculty at the University of Utah, during which time he was recognized annually with teaching awards. He is a Fellow in the American College of Physicians. Dr. Dere received his B.A. degree in Zoology and History and an M.D. degree from the University of California, Davis. He completed his internal medicine residency training at the University of Utah and his postdoctoral training in Endocrinology/Metabolism at the University of California at San Francisco.
Positions
- Company NameMetagenomi Therapeutics, Inc.Stock CodeMGXPositionIndependent Board ChairColleagues
- JIJian IrishCEO, President & Director
- PMPamela M. WapnickChief Financial Officer
- MLMatthew L. WeinGeneral Counsel, Compliance Officer, Head of BD&L and Corporate Secretary
- JKJoseph KnowlesCo-Founder & Member of Scientific Advisory Board
- MLMark LeonardSenior Vice President of Technical Development & Operations
- EHEric H. BjerkholtIndependent Director
- LELaurence E. ReidIndependent Director
- Company NameSeres Therapeutics, Inc.Stock CodeMCRBPositionIndependent DirectorColleagues
- RNRichard N. KenderInterim CEO & Executive Chair
- MRMatthew R. HennPresident & Chief Scientific Officer
- TJThomas J. DesRosierExecutive VP, Chief Legal Officer & Secretary
- KBKelly BradyExecutive VP & COO
- CMChris McChalicherExecutive VP & CTO
- KCKurt C. GravesIndependent Director
- WHWillard H. DereIndependent Director
- SAStephen A. BerensonIndependent Director
- EDEric D. ShaffDirector
